Pulse Biosciences Inc Dossier
Qualitative Analysis
Business overview
Pulse Biosciences, Inc. is a pioneering bioelectric medicine company focused on developing and commercializing its proprietary Nanosecond Pulsed-Field Ablation (nsPFA) technology. Operating under its patented CellFX brand, the company's platform delivers nanosecond-duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent noncellular tissue. Pulse Biosciences is actively advancing its clinical pipeline across multiple high-value medical specialties, including the CellFX nsPFA Cardiac Clamp for cardiac surgery, the CellFX nsPFA Cardiac Catheter for electrophysiology, and the CellFX nsPFA Percutaneous Electrode system for soft tissue ablation.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strategic prioritization of the nPulse Cardiac Catheter System for atrial fibrillation (AF) treatment following landmark clinical data demonstrating exceptional procedure efficiency and durable outcomes (96% rhythm control at 12 months in the EFS study). Resources are being reallocated to the EP program, while expenditures on the surgical clamp and thyroid programs are being optimized.
Expected impact: Establishes a highly differentiated, nonthermal nanosecond Pulsed Field Ablation (nsPFA) solution in the high-value cardiac electrophysiology market.
Executing a controlled launch of the Vybrance platform (utilizing the nPulse Vybrance Percutaneous Electrode System) for soft tissue ablation, specifically targeting benign and malignant thyroid tumors.
Expected impact: Generates early clinical adoption and real-world data to support broader commercial scaling and reimbursement pathways.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. The collaboration focuses on a first-in-human clinical feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating papillary thyroid microcarcinoma. It also includes ongoing preclinical studies to assess the effect of nsPFA energy on highly lethal anaplastic thyroid carcinoma.
Terms: Not explicitly disclosed; conducted under a research collaboration and material transfer agreement.